August 11, 2026 — The global High Risk IMDRF Category III & IV Software as a Medical Device market is projected to grow from USD 4.8 billion in 2026 to USD 16.9 billion by 2036, at a 13.4% CAGR, according to Fact.MR. Fact.MR also reports that the market reached USD 4.2 billion in 2025.

Demand is rising as healthcare providers use more software for diagnosis, clinical decisions, treatment, imaging and patient monitoring. Artificial intelligence and machine learning are adding more software functions that may require medical-device review. Hospitals also want software that connects with imaging systems and electronic health records while keeping clinical oversight and traceability. Cloud deployment is supporting access across multiple hospital sites, while frequent software updates are increasing the need for validation, cybersecurity and lifecycle controls.

Regulatory Evidence Supports Market Development

The market is also being shaped by regulatory work across major healthcare markets. Health Canada, the U.S. FDA and the UK MHRA published Good Machine Learning Practice guiding principles in 2021, according to the bibliography on the Fact.MR page. The same agencies published guiding principles for predetermined change control plans in 2024. The U.S. FDA's 2025 guidance covers lifecycle management and marketing submissions for AI-enabled device software functions. Japan's PMDA has maintained a dedicated SaMD review function, while its cited AI-based SaMD report dates to 2023. These dated regulatory references show the growing focus on evidence, lifecycle management and controlled software changes.

Get detailed market forecasts, competitive benchmarking, and pricing trends:   https://www.factmr.com/connectus/sample?flag=S&rep_id=16026

Key Numbers

Market Indicators — Fact.MR

• Market Size, 2025:USD 4.2 billion — MR
• Market Size, 2026:USD 4.8 billion — MR
• Market Forecast, 2036:USD 16.9 billion — MR
• CAGR, 2026–2036:4% — Fact.MR
• Absolute Dollar Opportunity:USD 12.1 billion — MR
• Diagnostic Software Share, 2026:0% — Fact.MR
• Medical Imaging Diagnostics Share, 2026:0% — Fact.MR
• Hospitals Share, 2026:0% — Fact.MR
• Cloud-based Deployment Share, 2026:0% — Fact.MR
• IMDRF Category III Share, 2026:0% — Fact.MR

All market figures and segment shares in this table are published by Fact.MR.

Segment Breakdown

Diagnostic Software leads Software Type. Fact.MR projects Diagnostic Software to hold 42.0% of the market in 2026. These products help identify or characterize diseases where incorrect or delayed results can affect treatment decisions.

Medical Imaging Diagnostics leads Application. Fact.MR gives Medical Imaging Diagnostics a 39.0% share in 2026. Software can analyze digital images, identify suspicious findings and help prioritize cases in existing radiology workflows.

Hospitals lead End User. Hospitals are projected to account for 44.0% in 2026. They manage serious and critical cases and have the specialist infrastructure needed for high-risk software deployment.

Cloud-based Deployment leads Deployment Model. Cloud-based Deployment is forecast to represent 56.0% in 2026. It can support centralized software updates and access across multiple clinical locations.

IMDRF Category III leads Risk Classification. Category III is projected to hold 61.0% in 2026. It covers software that informs critical clinical decisions or drives management in serious healthcare situations.

Country Growth Outlook

• USA:6% CAGR, 2026–2036
• Germany:1% CAGR, 2026–2036
• UK:7% CAGR, 2026–2036
• Japan:2% CAGR, 2026–2036
• Canada:8% CAGR, 2026–2036
• France:3% CAGR, 2026–2036
• Australia:8% CAGR, 2026–2036

Fact.MR forecasts the USA as the fastest-growing country in the supplied country comparison, at 14.6% CAGR. Germany follows at 14.1%, while the UK is forecast at 13.7%. Japan, Canada, France and Australia are projected at 13.2%, 12.8%, 12.3% and 11.8%, respectively.

Competitive Landscape

Fact.MR profiles Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Oracle Health, Epic Systems Corporation, Veradigm LLC and Aidoc Medical Ltd. in the market.

The source page does not publish individual market-share percentages for these companies. Therefore, no company share has been assigned in this release.

Competition centers on clinical evidence, regulatory approval, hospital integration, cybersecurity, software version control and post-market performance monitoring. Medical imaging and hospital-based clinical software are important areas for several of the profiled companies.

Analyst View

“Healthcare markets are entering a period of unprecedented innovation, with AI-enabled diagnostics, precision therapeutics, and digital health platforms converging to transform patient outcomes,” said Shambhu Nath Jha, Principal Consultant, Fact.MR. “Companies that integrate clinical evidence with digital capabilities will lead the next wave of healthcare transformation.”

Editorial note: Analyst quote requires Fact.MR sign-off before publication.

Frequently Asked Questions

How big is the high-risk IMDRF Category III & IV SaMD market in 2026?
Fact.MR values the market at USD 4.8 billion in 2026.

What will the high-risk SaMD market be worth in 2036?
The market is forecast to reach USD 16.9 billion by 2036.

What is the CAGR of the high-risk SaMD market from 2026 to 2036?
Fact.MR forecasts a 13.4% CAGR.

Which software type leads the high-risk SaMD market?
Diagnostic Software leads with a 42.0% share in 2026.

Which application leads the high-risk SaMD market?
Medical Imaging Diagnostics leads with a 39.0% share in 2026.

About Fact.MR

Fact.MR is a market research and advisory firm providing industry intelligence, market assessments and forecasts across global markets. The cited report uses a hybrid market assessment covering high-risk SaMD adoption, diagnostic and clinical-decision software demand, IMDRF risk classification, regulatory pathways, hospital deployment, AI and machine-learning integration, cloud delivery, cybersecurity, lifecycle controls and country-level adoption patterns. The page states that the analysis draws on 120+ sources, 35+ company portfolios, 25+ countries and more than 20 interviews.